Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Boschetti

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Inflammatory Bowel Diseases|November 16, 2016
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 YearsGilles Boschetti, Stephane Nancey, Fady Daniel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2019
Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's DiseaseNinon Soufflet, Gilles Boschetti, Xavier Roblin, et al.
The Journal of Allergy and Clinical Immunology|March 27, 2017
Intestinal dendritic cell licensing through Toll-like receptor 4 is required for oral tolerance in allergic contact dermatitisFeriel Hacini-Rachinel, Mercedes Gomez de Agüero, Reem Kanjarawi, et al.
Ebiomedicine|May 28, 2019
TRIM33 deficiency in monocytes and macrophages impairs resolution of colonic inflammationVanessa Petit, Aude Parcelier, Cecile Mathé, et al.
The American Journal of Gastroenterology|July 4, 2020
Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's DiseaseNassim Hammoudi, Claire Auzolle, My-Linh Tran Minh, et al.
Inflammatory Bowel Diseases|March 21, 2013
Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseasesStephane Nancey, Gilles Boschetti, Driffa Moussata, et al.
The American Journal of Gastroenterology|March 18, 2015
Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's DiseaseGilles Boschetti, Marc'harid Laidet, Driffa Moussata, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 29, 2016
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 MonthsNicolas Williet, Gilles Boschetti, Marion Fovet, et al.
Advanced Healthcare Materials|March 6, 2024
Peptide-Based Hydrogel for Nanosystems Encapsulation: the Next Generation of Localized Delivery Systems for the Treatment of Intestinal InflammationsValentina Andretto, Annalisa Rosso, Serena Zilio, et al.
Digestive Diseases and Sciences|January 2, 2021
Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's DiseaseFlorian Veyre, Gilles Boschetti, Camille Meunier, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Inflammatory Bowel Diseases|November 16, 2016
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 YearsGilles Boschetti, Stephane Nancey, Fady Daniel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2019
Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's DiseaseNinon Soufflet, Gilles Boschetti, Xavier Roblin, et al.
The Journal of Allergy and Clinical Immunology|March 27, 2017
Intestinal dendritic cell licensing through Toll-like receptor 4 is required for oral tolerance in allergic contact dermatitisFeriel Hacini-Rachinel, Mercedes Gomez de Agüero, Reem Kanjarawi, et al.
Ebiomedicine|May 28, 2019
TRIM33 deficiency in monocytes and macrophages impairs resolution of colonic inflammationVanessa Petit, Aude Parcelier, Cecile Mathé, et al.
The American Journal of Gastroenterology|July 4, 2020
Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's DiseaseNassim Hammoudi, Claire Auzolle, My-Linh Tran Minh, et al.
Inflammatory Bowel Diseases|March 21, 2013
Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseasesStephane Nancey, Gilles Boschetti, Driffa Moussata, et al.
The American Journal of Gastroenterology|March 18, 2015
Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's DiseaseGilles Boschetti, Marc'harid Laidet, Driffa Moussata, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 29, 2016
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 MonthsNicolas Williet, Gilles Boschetti, Marion Fovet, et al.
Advanced Healthcare Materials|March 6, 2024
Peptide-Based Hydrogel for Nanosystems Encapsulation: the Next Generation of Localized Delivery Systems for the Treatment of Intestinal InflammationsValentina Andretto, Annalisa Rosso, Serena Zilio, et al.
Digestive Diseases and Sciences|January 2, 2021
Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's DiseaseFlorian Veyre, Gilles Boschetti, Camille Meunier, et al.
Pageof 7